

RIBHI HAZIN, MD
Harvard University,
Faculty of Arts & Sciences,
Cambridge, MA

TAREK I. ABU-RAJAB TAMIMI, MD
Department of Gastroenterology
and Hepatology, Cleveland Clinic

JAMIL Y. ABUZETUN, MD
Department of Internal Medicine,
Creighton University Medical Center,
Omaha, NE

NIZAR N. ZEIN, MD
Mikati Foundation Endowed Chair in
Liver Diseases; Chief, Section of Hepatol-
ogy; Medical Director of Liver Transplan-
tation, Department of Gastroenterology
and Hepatology, Transplantation Center,
Cleveland Clinic

Recognizing and treating cutaneous signs of liver disease

ABSTRACT

Cutaneous changes may be the first clue that a patient has liver disease. Recognizing these signs is crucial to diagnosing liver conditions early. Here we describe the spectrum of skin manifestations that may be found in various liver diseases.

KEY POINTS

Pruritus due to liver disease is particularly resistant to therapy. Cholestyramine (Questran) 4 g/day, gradually increased to 24 g/day, is one option. If the pruritus does not respond or the patient cannot tolerate cholestyramine, rifampin (Rifadin) can be tried.

Spider angiomas, Bier spots, and “paper-money” skin are all superficial vascular problems that may be related to liver disease.

Cutaneous lesions often accompany alcoholic cirrhosis and have been detected in up to 43% of people with chronic alcoholism. The combination of spider angiomas, palmar erythema, and Dupuytren contracture is common in alcoholic cirrhosis.

Although porphyria cutanea tarda is associated with liver disease in general, recent studies show that patients with hepatitis C are at particularly high risk.

DYSFUNCTION IN THE BODY’S second largest organ, the liver, often yields changes in the body’s largest organ, the skin. If we can recognize these manifestations early, we are better able to promptly diagnose and treat the underlying liver disease, as well as the skin lesions.

The liver has many jobs: synthesizing proteins such as clotting factors, complements, and albumin; neutralizing toxins; and metabolizing lipids and carbohydrates. Insults to the liver can compromise any of these functions, affecting visceral organs, joints, gastrointestinal tissues, and the skin. Dermatologic signs of specific liver diseases include alopecia and vitiligo associated with autoimmune hepatitis, and xanthelasma in chronic cholestatic liver disease.

This article reviews the important cutaneous manifestations of specific liver diseases. We focus first on skin conditions that may represent liver disease, and then we discuss several major liver diseases and their typical cutaneous manifestations.

JAUNDICE AND HYPERBILIRUBINEMIA

Jaundice, the cardinal sign of hyperbilirubinemia, is usually recognizable when serum bilirubin levels exceed 2.5 or 3.0 mg/dL. The color of the skin typically reflects the severity of the bilirubin elevation.^{1,2} Jaundice due to mild hyperbilirubinemia tends to be yellowish, while that due to severe hyperbilirubinemia tends to be brownish (FIGURE 1).

Establishing whether the excess bilirubin is conjugated or unconjugated gives a clue as to whether the cause is prehepatic, intrahepatic, or posthepatic.^{3–8} One of the liver’s main func-



FIGURE 1. Characteristic yellowish discoloration of the sclera in the eye of a patient with end-stage liver disease.

Skin color typically reflects the severity of the jaundice

tions is to conjugate bilirubin into a secretable form. Prehepatic causes of jaundice include hemolysis and ineffective erythropoiesis, both of which lead to higher levels of circulating unconjugated bilirubin.⁴ Intrahepatic causes of jaundice can lead to both unconjugated and conjugated hyperbilirubinemia.^{4,8} Posthepatic causes such as bile duct obstruction primarily result in conjugated hyperbilirubinemia.⁴

■ **PRURITUS AND PRURIGO NODULARIS**

Pruritus can be multifactorial or the result of a specific dermatologic or systemic condition.⁹ A thorough history and physical examination are warranted to rule out hepatic or systemic causes of itching.¹⁰

The liver neutralizes toxins and filters bile salts. If its function is impaired, these materials can accumulate in the body, and deposition in the skin causes irritation and itching.^{11,12} In cholestatic liver disorders such as primary sclerosing cholangitis and obstructive gallstone disease, pruritus tends to be generalized, but worse on the hands and feet.¹³

Although the severity of pruritus is not directly associated with the level of bile salts and toxic substances, lowering bile salt levels can mitigate symptoms.¹¹

Treatment. Pruritus due to liver disease is particularly resistant to therapy.

In a strategy described by Mela et al for managing pruritus in chronic liver disease,¹⁴ the initial treatment is the anion exchange

resin cholestyramine (Questran) at a starting dose of 4 g/day, gradually increased to 24 g/day in two doses at mealtimes.

If the pruritus does not respond adequately to cholestyramine or the patient cannot tolerate the drug, then the antituberculosis drug rifampin (Rifadin) can be tried. Rifampin promotes metabolism of endogenous pruritogens and has been effective against cholestatic pruritus when started at 150 mg/day and increased up to 600 mg/day, depending on the clinical response.¹⁴

Third-line drug therapies include opioid antagonists such as naltrexone (ReVia) and nalmefene (Revex).^{14,15}

Plasmapheresis can be considered if drug therapy fails.¹⁶ Experimental therapies include albumin dialysis using the molecular adsorbent recirculating system (a form of artificial liver support), antioxidant treatment, and bright-light therapy.¹⁵ Liver transplantation, when appropriate, also resolves cholestatic pruritus.¹⁴

Prurigo nodularis

Prurigo nodularis, distinguished by firm, crusty nodules, is associated with viral infections (eg, hepatitis C, human immunodeficiency virus), bacterial infections, and kidney dysfunction.^{17,18} The lesions are intensely pruritic and often lead to persistent scratching, excoriation, and, ultimately, diffuse scarring.¹⁹

Treatment. Although the exact cause of prurigo nodularis is not known and no cure exists, corticosteroid or antihistamine ointments control the symptoms in most patients with hepatitis.¹⁹ Low doses of thalidomide (Thalomid), a tumor necrosis factor antagonist, have also been used safely and effectively.^{18,19}

■ **SUPERFICIAL VASCULAR SIGNS**

Spider angiomas

Spider angiomas, or spider nevi, are collections of dilated blood vessels near the surface of the skin.²⁰ They appear as slightly raised, small, reddish spots from which fine lines radiate outward, giving them a spider-like appearance (FIGURE 2).^{21,22}

Spider angiomas can occur anywhere on the body, but they occur most often on the face and the trunk.^{21,23} A key feature is that

they disappear when pressure is applied and reappear when pressure is removed.^{23,24} Biopsy is rarely necessary for diagnosis.

These lesions occur with elevated estrogen levels, such as in cirrhosis, during estrogen therapy, or during pregnancy.^{25–28} Although spider angiomas are common in pregnant women and in children, adults with spider angiomas deserve a workup for liver dysfunction.²⁹

Given their innocuous nature and asymptomatic course, spider angiomas themselves require no medical treatment.

Bier spots

Bier spots are small, irregularly shaped, hypopigmented patches on the arms and legs. They are likely due to venous stasis associated with functional damage to the small vessels of the skin.³⁰

Since Bier spots are a sign of liver disease, they must be distinguished from true pigmentation disorders. A key distinguishing feature is that Bier spots disappear when pressure is applied. Also, raising the affected limb from a dependent position causes the hypopigmented macules of Bier spots to disappear, which is not the case in true pigmentation disorders.^{10,30}

Paper-money skin

Paper-money skin (or “dollar-paper” markings) describes the condition in which the upper trunk is covered with many randomly scattered, needle-thin superficial capillaries. It often occurs in association with spider angiomas. The name comes from the resemblance the thread-like capillaries have to the finely chopped silk threads in American dollar bills.^{10,31} The condition is commonly seen in patients with alcoholic cirrhosis and may improve with hemodialysis.³¹

■ PALMAR ERYTHEMA

Palmar erythema is a florid, crimson coloration of the palms of the hands and the fingertips. It can occur anywhere on the palm and fingers but is most common on the hypothenar eminence. It can occur in a number of liver conditions but most often with cirrhosis.³² Hepatic compromise, as seen in alcoholic liver disease, disrupts the body’s androgen balance, causing local vasodilation and erythema.^{32,33} Although



FIGURE 2. Spider angiomas on the neck of an elderly patient with liver failure. Note the characteristic central vessel and symmetrically radiating thin branches.

the exact mechanism remains unknown, research suggests that prostacyclins and nitric oxide play a role, as both are increased in liver disease.^{32,33}

■ XANTHELASMA

Xanthelasma—a localized cholesterol deposit beneath the skin and especially beneath the eyelids—is a common manifestation of hypercholesterolemia. Xanthelasma often presents as a painless, yellowish, soft plaque with well-defined borders,³⁴ which may enlarge over the course of weeks.

Several liver diseases can lead to various forms of secondary dyslipoproteinemia.³⁵ The most common dyslipoproteinemias in liver disease are hypertriglyceridemia and low levels of high-density lipoprotein cholesterol, and both of these often accompany fatty liver disease.³⁶ Hypercholesterolemia is a common feature of primary biliary cirrhosis and other forms of cholestatic liver disease.³⁷ Studies suggest that the total plasma cholesterol level is elevated in as many as 50% of patients with compromised liver function.³⁸

Treatment. The underlying hyperlipidemia is treated with cholesterol-lowering drugs. Laser treatment and surgical excision have proven efficacious in treating the lesions.³⁹

Eyelid xanthelasma indicates high cholesterol, a sign of cholestatic liver disease



FIGURE 3. Onycholysis in a patient with liver disease exhibiting characteristic separation of the nail plate distally.

■ **OTHER CUTANEOUS FINDINGS IN LIVER DISEASE**

Bleeding and bruising. Liver disease can cause hypersplenism and thrombocytopenia, in addition to a decrease in clotting factors. These may present with a myriad of cutaneous symptoms, including purpura, bleeding gums, and easy bruising and bleeding, even from minor trauma.^{40–42}

Hyperpigmentation of the skin may accompany hemochromatosis, alcoholic liver disease, and cirrhosis.^{43–45}

Hair and nail loss. Patients with hepatocellular dysfunction may develop hair-thinning or hair loss and nail changes such as clubbing, leukonychia (whitening), or onycholysis, affecting the nails of the hands and feet (**FIGURE 3**).^{46,47}

“**Terry’s nails,**” in which the proximal two-thirds of the nail plate turns powdery white with a ground-glass opacity, may develop in patients with advanced cirrhosis.⁴⁸

■ **ALCOHOLIC CIRRHOSIS AND THE SKIN**

The cutaneous changes associated with alcoholic cirrhosis are more widely recognized than those due to other forms of liver dysfunction. In the United States, approximately 3 million people have alcoholic cirrhosis, the second-leading reason for liver transplantation.^{49,50}

As the body’s main site of alcohol me-

tabolism, the liver is the organ most affected by excessive alcohol intake, which can lead to end-stage liver disease secondary to alcoholic cirrhosis.^{41,51} The characteristic feature of cirrhosis is advanced fibrous scarring of parenchymal tissue and the formation of regenerative nodules with increased resistance to blood flow throughout the organ.^{41,52} The insufficient blood flow damages vital structures in the liver and compromises liver function. For example, liver cirrhosis leads to defective hepatic synthesis of clotting factors and results in bleeding disorders.

Cutaneous lesions often accompany alcoholic cirrhosis and have been detected in up to 43% of people with chronic alcoholism.⁵³ Skin changes in alcoholic cirrhosis can be of great diagnostic value. The combined prevalence of spider angiomas, palmar erythema, and Dupuytren contracture in alcoholic cirrhosis was found to be 72%. Paper-money skin and Dupuytren contracture are more distinct lesions for alcoholic cirrhosis.³¹ Recognizing these skin changes contributes to the diagnosis and staging of liver cirrhosis.^{51,52}

Dupuytren contracture

Dupuytren contracture is characterized by progressive fibrosis and thickening of tendons in the palmar fascia, the connective tissue that lies beneath the skin of the palms.⁵⁴ Over time, as fibrotic involvement expands across the fascia, rampant stiffness of the joints ensues, sometimes to a point where the fingers cannot fully flex or extend.⁵⁴

Although the exact cause of Dupuytren contracture is unknown, it appears to be associated with excess alcohol consumption and can be found in patients with alcoholic cirrhosis.^{54,55} These patients often present with painless stiffness of the fingers, curling of fingers, and loss of motion in involved fingers.⁵⁴ Surgery in the form of limited fasciectomy has been curative in such patients.⁵⁴

Disseminated superficial porokeratosis

Porokeratosis is a keratinization disorder of clonal origin that presents as a linear configuration of white scaly papules that coalesce into plaques throughout the body.⁵⁶ Although it most commonly afflicts fair-skinned people, patients with alcoholic cirrhosis have a

Paper-money skin and Dupuytren contracture may signal alcoholic cirrhosis

much greater susceptibility than the general population.^{57,58}

A recent study⁵⁸ documented that the lesions completely resolved when liver function improved, thus underlining the relationship between the two conditions. Since immunosuppression has been linked to eruption of the lesion, the fact that both humoral and cell-mediated immune responses are impaired in alcoholic liver disease provides another dimension to the association between porokeratosis and alcoholic cirrhosis.⁵⁸

These lesions can transform into squamous cell carcinoma.⁵⁹ The risk of widespread metastases in squamous cell carcinoma highlights the importance of dermatologic consultation in such patients.⁵⁹

HEPATITIS C AND THE SKIN

Extrahepatic manifestations have been documented in up to 74% of people with hepatitis C virus infection.⁶⁰ In addition to paresthesias, arthralgias, and myalgias, hepatitis C has a significant association with porphyria cutanea tarda, lichen planus, vitiligo, sialadenitis, urticarial vasculitis, corneal ulcers, xerosis, pruritus, and prurigo nodularis.⁶⁰⁻⁶⁴ Although the primary causative agents of sialadenitis are bacteria, viruses such as hepatitis C have been implicated as a cause of chronic sialadenitis with associated xerostomia.⁶⁵

Patients with hepatitis C being treated with interferons also present with cutaneous manifestations such as hyperkeratosis and vasculitis.⁶³

Porphyria cutanea tarda

Porphyria cutanea tarda is the most common of the porphyrias, disorders distinguished by deficiencies or defects in one or more of the enzymes responsible for hepatic production of heme.⁶⁶ If these enzymes are impaired, heme precursors such as porphyrins accumulate.⁶⁶

Porphyria cutanea tarda results from a deficiency of the hepatic enzyme uroporphyrin decarboxylase. In the absence of this enzyme, shortwave visible light activates uroporphyrin deposited in the skin, resulting in a photochemical reaction that generates reactive oxygen species that lead to the characteristic skin blistering.



FIGURE 4. Permanent hair loss from lichen planopilaris in a patient with chronic hepatitis C virus infection.

Although porphyria cutanea tarda is associated with liver disease in general, recent studies confirm that patients with hepatitis C are at particularly high risk.⁶⁷ Those with the disorder often present with skin photosensitivity.⁶⁸ Many develop blisters on sun-exposed skin, including the dorsal aspects of the hands and forearms and on the neck and face. Chronic porphyria cutanea tarda can lead to scarring, alopecia, and skin ulceration.⁶⁹ As the blisters heal, keratin-filled milial cysts may develop in the areas of ulceration.

The condition is also commonly associated with melasma-like hyperpigmentation and hypertrichosis in sun-exposed areas of the head and neck. People of Northern European ancestry may be more at risk than the general population because of a presumed genetic susceptibility.⁷⁰

Treatment. Because many patients with porphyria cutanea tarda have iron overload, they need to restrict foods rich in iron and to avoid alcohol.^{71,72} Severe cases may necessitate iron removal via phlebotomy or antimalarial therapy. Patients with porphyria cutanea tarda induced by hepatitis C should have their bodily iron stores depleted before starting antiviral therapy.⁶⁰

Lichen planus

Lichen planus is a chronic pruritic, papular condition that often presents clinically with

Porokeratosis can transform into squamous cell carcinoma

the “five P’s”: pruritic, planar, polygonal, purple papules. It can occur throughout the body but typically affects the wrists and ankles, causing mild to severe itching in most affected people.⁷³ In about 50% of patients, the lesions resolve within 6 months, and in 85% they subside within 18 months.⁷⁴

Lichen planopilaris is a subset of lichen planus that causes scaling and atrophy of the scalp and permanent hair loss (FIGURE 4).⁷³

Interferon-induced vitiligo

Vitiligo is an autoimmune disease in which melanocytes in the skin are destroyed, with resulting depigmentation in affected areas.⁷⁵ Although it has no specific association with liver disease, it has been linked to treatments for hepatitis C such as interferons.⁷⁶ Interferon-induced vitiligo often completely resolves when interferon is stopped.⁷⁷

Typical findings include aggregations of irregularly shaped white patches in a focal or segmental pattern.⁷⁸ The diagnosis is based on the medical history, physical examination, and sometimes skin biopsy.

HEMOCHROMATOSIS

Hemochromatosis or “bronze diabetes” is a devastating multisystem disease with a relentless course. It is among the most common genetic disorders of metabolism, and results in deposition of iron in tissues and organs throughout the body, including the liver, usually in patients ages 30 to 40.

As iron stores increase in tissues and organs, multiorgan failure and associated complications may ensue. In addition, surplus iron stores can also result in widespread bronze dis-

coloration of skin exposed to the sun. Hemochromatosis also results in loss of body hair, ichthyosiform alterations, and koilonychia.⁷⁹

Treatments that lower serum iron levels can reverse the cutaneous manifestations of the disorder and minimize the risk of organ failure.

Since the condition is inherited in an autosomal-recessive pattern, family members of patients should consider being screened.⁸⁰

Hyperpigmentation in hemochromatosis

Hyperpigmentation is an early sign of hemochromatosis, affecting up to 90% of patients. Usually, sun-exposed areas of the body are the most prone and take on a grayish or brownish-bronze hue.⁸¹ Cutaneous iron deposits injure vital skin structures, initiating a process that culminates in enhanced melanin production by melanocytes.⁸² Exposure to ultraviolet light may have synergistic effects with iron, hastening the process of hyperpigmentation. As a result of this synergistic effect, many patients with hemochromatosis notice tanning with minimal sun exposure.

Although organ function can improve immediately with phlebotomy to reduce iron stores, skin hyperpigmentation does not immediately resolve.^{81,82}

Ichthyosiform alterations in hemochromatosis

Ichthyosiform changes, in which the skin takes on the appearance of fish scales,⁸³ can be seen in patients with hemochromatosis.⁸⁰ Affected areas typically become extremely dry. Treatment includes topical hydrating creams and ointments. Avoiding sunlight is paramount, as sunlight exposure may exacerbate the condition.⁸³

REFERENCES

- Morioka D, Togo S, Kumamoto T, et al. Six consecutive cases of successful adult ABO-incompatible living donor liver transplantation: a proposal for grading the severity of antibody-mediated rejection. *Transplantation* 2008; 85:171–178.
- Bertini G, Rubaltelli FF. Non-invasive bilirubinometry in neonatal jaundice. *Semin Neonatol* 2002; 7:129–133.
- Clementi M, Di Gianantonio E, Fabris L, et al. Inheritance of hyperbilirubinemia: evidence for a major autosomal recessive gene. *Dig Liver Dis* 2007; 39:351–355.
- Roche SP, Kobos R. Jaundice in the adult patient. *Am Fam Physician* 2004; 69:299–304.
- Odemis B, Parlak E, Basar O, Yüksel O, Sahin B. Biliary tract obstruction secondary to malignant lymphoma: experience at a referral center. *Dig Dis Sci* 2007; 52:2323–2332.
- Caddy GR, Tham TC. Gallstone disease: symptoms, diagnosis and endoscopic management of common bile duct stones. *Best Pract Res Clin Gastroenterol* 2006; 20:1085–1101.
- Heathcote EJ. Diagnosis and management of cholestatic liver disease. *Clin Gastroenterol Hepatol* 2007; 5:776–782.
- Faust TW, Reddy KR. Postoperative jaundice. *Clin Liver Dis* 2004; 8:151–166.
- Maticic M, Poljak M, Lunder T, Renner-Sitar K, Stojanovic L. Lichen planus and other cutaneous manifestations in chronic hepatitis C: pre- and post-interferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area. *J Eur Acad Dermatol Venereol* 2008; 22:779–788.
- Polat M, Oztas P, Ilhan MN, Yalçin B, Alli N. Generalized pruritus: a prospective study concerning etiology. *Am J Clin Dermatol* 2008; 9:39–44.
- Gaspari R, Avolio AW, Zileri Dal Verme L, et al. Molecular adsorbent

- recirculating system in liver transplantation: safety and efficacy. *Transplant Proc* 2006; 38:3544–3551.
12. **Dasgupta R, Saha I, Pal S, et al.** Immunosuppression, hepatotoxicity and depression of antioxidant status by arecoline in albino mice. *Toxicology* 2006; 227:94–104.
 13. **Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ.** Sertraline as a first-line treatment for cholestatic pruritus. *Hepatology* 2007; 45:666–674.
 14. **Mela M, Mancuso A, Burroughs AK.** Review article: pruritus in cholestatic and other liver diseases. *Aliment Pharmacol Ther* 2003; 17:857–870.
 15. **Montero JL, Pozo JC, Barrera P, et al.** Treatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MARS). *Transplant Proc* 2006; 38:2511–2513.
 16. **Neff GW, O'Brien CB, Reddy KR, et al.** Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. *Am J Gastroenterol* 2002; 97:2117–2119.
 17. **Neri S, Raciti C, D'Angelo G, Ierna D, Bruno CM.** Hyde's prurigo nodularis and chronic HCV hepatitis. *J Hepatol* 1998; 28:161–164.
 18. **Brown MA, George CR, Dunstan CR, Kalowski S, Corrigan AB.** Prurigo nodularis and aluminium overload in maintenance haemodialysis. *Lancet* 1992; 340:48.
 19. **Stander S, Luger T, Metzke D.** Treatment of prurigo nodularis with topical capsaicin. *J Am Acad Dermatol* 2001; 44:471–478.
 20. **Requena L, Sanguenza OP.** Cutaneous vascular anomalies. Part I. Hamartomas, malformations, and dilation of preexisting vessels. *J Am Acad Dermatol* 1997; 37:523–549.
 21. **Khasnis A, Gokula RM.** Spider nevus. *J Postgrad Med* 2002; 48:307–309.
 22. **Kaul V, FriedenberG FK, Braitman LE, et al.** Development and validation of a model to diagnose cirrhosis in patients with hepatitis C. *Am J Gastroenterol* 2002; 97:2623–2628.
 23. **Banyai AL.** There is more than surface appearance to skin spiders. *Chest* 1971; 60:48.
 24. **Errickson CV, Matus NR.** Skin disorders of pregnancy. *Am Fam Physician* 1994; 49:605–610.
 25. **Li CP, Lee FY, Hwang SJ, et al.** Spider angiomas in patients with liver cirrhosis: role of alcoholism and impaired liver function. *Scand J Gastroenterol* 1999; 34:520–523.
 26. **Li CP, Lee FY, Hwang SJ, et al.** Role of substance P in the pathogenesis of spider angiomas in patients with nonalcoholic liver cirrhosis. *Am J Gastroenterol* 1999; 94:502–507.
 27. **Sadick NS, Niedt GW.** A study of estrogen and progesterone receptors in spider telangiectasias of the lower extremities. *J Dermatol Surg Oncol* 1990; 16:620–623.
 28. **Henry F, Quatresooz P, Valverde-Lopez JC, Pierard GE.** Blood vessel changes during pregnancy: a review. *Am J Clin Dermatol* 2006; 7:65–69.
 29. **Finn SM, Rowland M, Lawlor F, et al.** The significance of cutaneous spider naevi in children. *Arch Dis Child* 2006; 91:604–605.
 30. **Peyrot I, Boulinguez S, Sparsa A, Le Meur Y, Bonnetblanc JM, Bedane C.** Bier's white spots associated with scleroderma renal crisis. *Clin Exp Dermatol* 2007; 32:165–167.
 31. **Satoh T, Yokozeki H, Nishioka K.** Vascular spiders and paper money skin improved by hemodialysis. *Dermatology* 2002; 205:73–74.
 32. **Serrao R, Zirwas M, English JC.** Palmar erythema. *Am J Clin Dermatol* 2007; 8:347–356.
 33. **Matsumoto M, Ohki K, Nagai I, Oshibuchi T.** Lung traction causes an increase in plasma prostacyclin concentration and decrease in mean arterial blood pressure. *Anesth Analg* 1992; 75:773–776.
 34. **Otto AI, Horvath I, Feldmann J.** Multiple firm, painless erythematous papules with a yellowish hue. *Arch Dermatol* 2005; 141:1595–1600.
 35. **Gandelman G, Aronow WS, Weiss MB.** Resolving hyperlipidemia after liver transplantation in a patient with primary sclerosing cholangitis. *Am J Ther* 2006; 13:171–174.
 36. **Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G.** Fatty infiltration of liver in hyperlipidemic patients. *Dig Dis Sci* 2000; 45:1929–1934.
 37. **Allocca M, Crosignani A, Gritti A, et al.** Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. *Gut* 2006; 55:1795–1800.
 38. **Dickson E, Fleming C, Ludwig J.** Primary biliary cirrhosis. In: Popper H, Schaffner F, editors. *Progress in Liver Diseases*. New York: Grune and Stratton; 1978:487.
 39. **Einer VM, Mintz R, Demirci H, Hassan AS.** Local corticosteroid treatment of eyelid and orbital xanthogranuloma. *Trans Am Ophthalmol Soc* 2005; 103:69–73.
 40. **Craxi A, Camma C, Giunta M.** Clinical aspects of bleeding complications in cirrhotic patients. *Blood Coagul Fibrinolysis* 2000; 11(suppl 1):S75–S79.
 41. **Kajihara M, Okazaki Y, Kato S, et al.** Evaluation of platelet kinetics in patients with liver cirrhosis: similarity to idiopathic thrombocytopenic purpura. *J Gastroenterol Hepatol* 2007; 22:112–118.
 42. **Levine N.** Patient reports six-month history of minimally pruritic purple dots on legs. Non-blanching macules developed over six months. *Geriatrics* 2006; 61:22.
 43. **Barton JC, Rao SV, Pereira NM, et al.** Juvenile hemochromatosis in the southeastern United States: a report of seven cases in two kinships. *Blood Cells Mol Dis* 2002; 29:104–115.
 44. **Smith AG, Shuster S, Bomford A, Williams R.** Plasma immunoreactive beta-melanocyte-stimulating hormone in chronic liver disease and fulminant hepatic failure. *J Invest Dermatol* 1978; 70:326–327.
 45. **Barton JC, McDonnell SM, Adams PC, et al.** Management of hemochromatosis. Hemochromatosis Management Working Group. *Ann Intern Med* 1998; 129:932–939.
 46. **Bahnsen M, Gluud C, Johnsen SG, et al.** Pituitary-testicular function in patients with alcoholic cirrhosis of the liver. *Eur J Clin Invest* 1981; 11:473–479.
 47. **Kumar N, Aggarwal SR, Anand BS.** Comparison of truncal hair distribution in alcoholic liver disease and alcohol-related chronic pancreatitis. *J Gastroenterol Hepatol* 2001; 16:855–856.
 48. **Holzberg M, Walker HK.** Terry's nails: revised definition and new correlations. *Lancet* 1984; 1:896–899.
 49. **Mandayam S, Jamal MM, Morgan TR.** Epidemiology of alcoholic liver disease. *Semin Liver Dis* 2004; 24:217–232.
 50. **Belle SH, Beringer KC, Detre KM.** Liver transplantation in the United States: results from the National Pitt-UNOS Liver Transplant Registry. United Network for Organ Sharing. *Clin Transpl* 1994:19–35.
 51. **Dunn W, Xu R, Schwimmer JB.** Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. *Hepatology* 2008; 47:1947–1954.
 52. **Afford SC, Fisher NC, Neil DA, et al.** Distinct patterns of chemokine expression are associated with leukocyte recruitment in alcoholic hepatitis and alcoholic cirrhosis. *J Pathol* 1998; 186:82–89.
 53. **Evstaf'ev VV, Levin MM.** Dermatologic pathology in chronic alcoholics. *Vestn Dermatol Venerol* 1989; 8:72–74.
 54. **Jerosch-Herold C, Shepstone L, Chojnowski AJ, Larson D.** Splinting after contracture release for Dupuytren's contracture (SCoRD): protocol of a pragmatic, multi-centre, randomized controlled trial. *BMC Musculoskelet Disord* 2008; 9:62.
 55. **Houghton S, Holdstock G, Cockerell R, Wright R.** Dupuytren's contracture, chronic liver disease and IgA immune complexes. *Liver* 1983; 3:220–224.
 56. **Ibbotson SH.** Disseminated superficial porokeratosis: what is the association with ultraviolet radiation? *Clin Exp Dermatol* 1996; 21:48–50.
 57. **Kono T, Kobayashi H, Ishii M, Nishiguchi S, Taniguchi S.** Synchronous development of disseminated superficial porokeratosis and hepatitis C virus-related hepatocellular carcinoma. *J Am Acad Dermatol* 2000; 43:966–968.
 58. **Park BS, Moon SE, Kim JA.** Disseminated superficial porokeratosis in a patient with chronic liver disease. *J Dermatol* 1997; 24:485–487.
 59. **Murata Y, Kumano K, Takai T.** Type 2 segmental manifestation of disseminated superficial porokeratosis showing a systematized pattern of involvement and pronounced cancer proneness. *Eur J Dermatol* 2001; 11:191–194.
 60. **Galossi A, Guarisco R, Bellis L, Puoti C.** Extrahepatic manifestations of chronic HCV infection. *J Gastrointest Liver Dis* 2007; 16:65–73.
 61. **El-Serag HB, Hampel H, Yeh C, Rabeneck L.** Extrahepatic manifesta-

- tions of hepatitis C among United States male veterans. *Hepatology* 2002; 36:1439–1445.
62. **Stefanova-Petrova DV, Tzvetanska AH, Naumova EJ, et al.** Chronic hepatitis C virus infection: prevalence of extrahepatic manifestations and association with cryoglobulinemia in Bulgarian patients. *World J Gastroenterol* 2007; 13:6518–6528.
 63. **Vassilopoulos D, Calabrese LH.** Extrahepatic immunological complications of hepatitis C virus infection. *AIDS* 2005; 19(suppl 3):S123–S127.
 64. **Hsing AW, Zhang M, Rashid A, et al.** Hepatitis B and C virus infection and the risk of biliary tract cancer: a population-based study in China. *Int J Cancer* 2008; 122:1849–1853.
 65. **Madrid C, Courtois B, Duran D.** Chronic sialadenitis revealing hepatitis C: a case report. *Med Oral* 2004; 9:328–332.
 66. **Lançon G, Ravinal RC, Costa RS, Roselino AM.** Mast cells and transforming growth factor-beta expression: a possible relationship in the development of porphyria cutanea tarda skin lesions. *Int J Dermatol* 2008; 47:575–581.
 67. **Toll A, Celis R, Ozalla MD, Bruguera M, Herrero C, Ercilla MG.** The prevalence of HFE C282Y gene mutation is increased in Spanish patients with porphyria cutanea tarda without hepatitis C virus infection. *J Eur Acad Dermatol Venereol* 2006; 20:1201–1206.
 68. **Badminton MN, Elder GH.** Management of acute and cutaneous porphyrias. *Int J Clin Pract* 2002; 56:272–278.
 69. **Jackson JM, Callen JP.** Scarring alopecia and sclerodermatous changes of the scalp in a patient with hepatitis C infection. *J Am Acad Dermatol* 1998; 39:824–826.
 70. **Mortimore M, Merryweather-Clarke AT, Robson KJ, Powell LW.** The haemochromatosis gene: a global perspective and implications for the Asia-Pacific region. *J Gastroenterol Hepatol* 1999; 14:838–843.
 71. **Shehan JM, Huerter CJ.** Porphyria cutanea tarda associated with an acute gastrointestinal bleed: the roles of supplemental iron and blood transfusion. *Cutis* 2001; 68:147–150.
 72. **Lambrech RW, Thapar M, Bonkovsky HL.** Genetic aspects of porphyria cutanea tarda. *Semin Liver Dis* 2007; 27:99–108.
 73. **d'Ovidio R, Sgarra C, Conserva A, Angelotti UF, Erriquez R, Foti C.** Altered integrin expression in lichen planopilaris. *Head Face Med* 2007; 3:11.
 74. **Chuang TY, Stitle L, Brashear R, Lewis C.** Hepatitis C virus and lichen planus: a case-control study of 340 patients. *J Am Acad Dermatol* 1999; 41:787–789.
 75. **Kemp EH, Gavalas NG, Gawkrödger DJ, Weetman AP.** Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. *Autoimmun Rev* 2007; 6:138–142.
 76. **Tomasiewicz K, Modrzewska R, Semczuk G.** Vitiligo associated with pegylated interferon and ribavirin treatment of patients with chronic hepatitis C: a case report. *Adv Ther* 2006; 23:139–142.
 77. **Simsek H, Savas C, Akkiz H, Telatar H.** Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection. *Dermatology* 1996; 193:65–66.
 78. **Mulekar SV, Al Issa A, Asaad M, Ghwish B, Al Eisa A.** Mixed vitiligo. *J Cutan Med Surg.* 2006; 10:104–107.
 79. **Waalén J, Felitti V, Gelbart T, Ho NJ, Beutler E.** Prevalence of hemochromatosis-related symptoms among individuals with mutations in the HFE gene. *Mayo Clin Proc* 2002; 77:522–530.
 80. **Walker AP, Tucker DC, Hall MA, et al.** Results communication and patient education after screening for possible hemochromatosis and iron overload: experience from the HEIRS study of a large ethnically and linguistically diverse group. *Genet Med* 2007; 9:778–791.
 81. **Stulberg DL, Clark N, Tovey D.** Common hyperpigmentation disorders in adults: Part I. Diagnostic approach, café au lait macules, diffuse hyperpigmentation, sun exposure, and phototoxic reactions. *Am Fam Physician* 2003; 68:1955–1960.
 82. **Tsuji T.** Experimental hemosiderosis: relationship between skin pigmentation and hemosiderin. *Acta Derm Venereol* 1980; 60:109–114.
 83. **Oji V, Traupe H.** Ichthyoses: differential diagnosis and molecular genetics. *Eur J Dermatol* 2006; 16:349–359.

.....
ADDRESS: Nizar N. Zein, MD, Department of Gastroenterology and Hepatology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail zeinn@ccf.org.